Perfil
Pierre Thibault is the founder of Epitopea Ltd.
founded in 2021.
Dr. Thibault is also the founder of SpecificiT Pharma, Inc.
Cargos activos de Pierre Thibault
| Empresas | Cargo | Inicio |
|---|---|---|
SpecificiT Pharma, Inc.
 SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada. | Fundador | - |
Antiguos cargos conocidos de Pierre Thibault.
| Empresas | Cargo | Fin |
|---|---|---|
Epitopea Ltd.
 Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Fundador | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
SpecificiT Pharma, Inc.
SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada. | Commercial Services |
Epitopea Ltd.
Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Commercial Services |
- Bolsa de valores
- Insiders
- Pierre Thibault